We are a trusted partner
Our clients
User cases / Success stories
« We are applying jinkō’s virtual population simulation technology and in silico research approach as a complement to clinical development plans to support health technology assessment for our innovative therapies. »
Thierry Marquet
General Manager, Takeda France
Thierry Marquet
General Manager, Takeda France
Apply for a new marketing authorization and present new results to demonstrate the higher efficacy of Natpar compared to the standard of care.
Reduce payer uncertainty to speed up acceptance and allow rare disease patients to access Natpar earlier.
« Generating such insights upstream, within a few months instead of many years, reduces risk and directs more successful drug development strategies. »
Pietro Scalfaro
Chief Medical Officer
Pietro Scalfaro
Chief Medical Officer
Find an efficient way to identify the best possible treatment combinations among
hundreds (if not thousands) of possibilities
Phase II
Disease model:
HBV
HBV
Treatment model:
Vonafexor (FXR agonist)
Vonafexor (FXR agonist)
Assessing Vonafexor’s efficacy in combination with different SoC regimens in +700 different trial designs
to identify the best protocol for ENYO’s next clinical trial
Contact us
What to learn more on how we can increase your chances of clinical trial success? Please fill out this form and we will get back to you asap!